CHESTER, N.J. and SLOUGH, England, Dec. 21 /PRNewswire-FirstCall/ --
Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser"), today commenced
its previously announced cash tender offer (the "Offer") for all of the
outstanding shares of Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT)
As announced on December 10, 2007, Reckitt Benckiser has entered into a
definitive agreement under which it will offer Adams stockholders US$60.00
in cash for each Adams share they hold. This offer is being made through
Twickenham Inc., a wholly owned subsidiary of Reckitt Benckiser. Adams'
Board of Directors has unanimously determined that the offer is fair to and
in the best interests of Adams' stockholders and recommended that holders
of Adams common stock accept the offer and tender their shares in the
The Offer represents a total offer value of approximately US$2.3
billion (1.1 billion pounds Sterling), and will expire on January 23, 2008,
The Offer is made directly to the stockholders of Adams and is
conditioned upon, among other things, the tender of a majority of Adams'
outstanding shares of common stock and the expiration or termination of the
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Any
common shares not acquired in the Offer are expected to be acquired in a
subsequent merger at the same price as the Offer.
Stockholders of Adams are advised to read the important information
contained in the Tender Offer Statement on Schedule TO, the Offer to
Purchase and any other documents relating to the Offer that are filed by
Reckitt Benckiser and Twickenham with the Securities and Exchange
Commission (SEC). In addition, Adams will file with the SEC a
Solicitation/Recommendation Statement on Schedule 14D-9 relating to the
offer. Stockholders of Adams may obtain copies of these documents for free,
when available, at the SEC's website at www.sec.gov or by calling
Georgeson, Inc., the Information Agent for the Offer, at (800) 456-6112 (US
Notice to Investors: This announcement is neither an offer to purchase
nor a solicitation of an offer to sell securities. The tender offer
statement being filed with the SEC on Schedule TO (including an offer to
purchase, a related letter of transmittal and other offer documents) and
the solicitation/ recommendation statement being filed with the SEC on
Schedule 14D-9 contain important information that should be read carefully
before any decision is made with respect to the tender offer. Those
materials will be made available to Adams' security holders at no expense
to them. In addition, all of those materials (and all other offer documents
filed with the SEC) will be available at no charge on the SEC's Web site:
Forward-looking Statements: This press release contains certain
"forward- looking" statements, including the expected timetable for
completing the proposed transaction between Reckitt Benckiser and Adams.
Such forward-looking statements can be identified by the words "intend,"
"expect," and similar expressions and are subject to risks and
uncertainties that could cause actual results to differ materially from
those in the forward-looking statements. Factors that could cause actual
results to differ materially include, among others, the satisfaction of
conditions to the closing of the proposed transaction; general economic,
business and market conditions; and other risk factors set forth under Item
1A. Risk Factors in Adams' Annual Report on Form 10-K for the fiscal year
ended June 30, 2007 and under Item 1A. Risk Factors in Adams' Quarterly
Report on Form 10-Q for the quarter ended September 30, 2007. Except to the
extent required by applicable securities laws, we are not under any
obligation to (and expressly disclaim any such obligation to) update any
forward-looking statements, whether as a result of new information, future
events, or otherwise. All statements contained in this press release are
made only as of the date of this release.
Notes for Editors
Reckitt Benckiser is a world leader in household cleaning, health and
personal care. The Company is truly global, with over 60 operating
companies and some 43 manufacturing facilities worldwide and has sales in
180 countries. The Company employs 22,000 people around the world. Amongst
the Company's leading brands in household are Lysol, the world leader in
disinfecting cleaning, Calgonit & Finish & Electrasol, the world leaders in
automatic dishwashing, Woolite, world leader in fine fabrics, Vanish &
Spray'nWash, world leaders in fabric treatment, Airwick and Mortein, both
No.2 brands in air care and pest control respectively. In Health & Personal
Care (25% of net revenues), leading brand positions include Veet, the world
number one depilatory and Dettol the world's leading antiseptic, Nurofen,
the leading European analgesic, Strepsils, world number one in medicated
sore throat, Gaviscon the No.1 gastro intestinal remedy in UK and Lemsip
the UK No.1 in cold/flu remedies.
Reckitt Benckiser is headquartered in Slough just outside London, UK
and is listed on the London stock exchange. With a market capitalization of
c. 20bn pounds it ranks among the top 25 UK listed companies. Reckitt
Benckiser had net revenues of 4.92bn pounds, operating profit of 910m
pounds, and net income of 674m pounds in 2006.
About Adams Respiratory Therapeutics, Inc.
Adams is a specialty pharmaceutical company focused on the late-stage
development, commercialization and marketing of over-the-counter and
prescription pharmaceuticals for the treatment of respiratory disorders.
SOURCE Reckitt Benckiser Group plc